Japan's Yamatake Licenses OGT's Oligo IP to Develop Microarrays

Aug 08, 2006

NEW YORK (GenomeWeb News) – Japan’s Yamatake has licensed Oxford Gene Technology’s oligonucleotide microarray patents to make and sell its own arrays, OGT said today.

Yamatake will manufacture gemkey microarrays using in situ synthesis. Yamatake is the only Japanese company using in situ synthesis, said Michael Bennett, OGT’s vice president of licensing.

The company will market the microarrays through its distributor, Sigma-Aldrich Japan.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Dual Listings Sought

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

Allocating the Grant Pie

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

More Proposed for NSF

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

This Week in PNAS

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Featured White Papers

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

Optimized NGS Library Preparation with Acoustic Liquid Handling

Jun

21

Featured Webinar

Evaluation & Implementation of NGS Liquid Biopsy Assays

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.

Main menu